LIR Life Sciences Corp. SKNY
CNSX
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -3.43M | -2.82M | -1.96M | -- | -- |
| Total Depreciation and Amortization | 2.90K | 3.70K | 2.80K | -- | -- |
| Total Amortization of Deferred Charges | -2.70K | -2.70K | 236.30K | -- | -- |
| Total Other Non-Cash Items | 1.76M | 1.47M | 489.10K | -- | -- |
| Change in Net Operating Assets | -50.00K | -120.60K | 900.00 | -- | -- |
| Cash from Operations | -1.73M | -1.48M | -1.23M | -- | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 1.10M | 1.10M | 1.03M | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | -76.40K | -76.40K | -- | -- |
| Cash from Investing | 1.10M | 1.02M | 949.20K | -- | -- |
| Total Debt Issued | 5.00K | 40.00K | 40.00K | -- | -- |
| Total Debt Repaid | -- | -- | -257.50K | -- | -- |
| Issuance of Common Stock | 1.07M | 1.07M | 1.14M | -- | -- |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.40K | -3.40K | -8.00K | -- | -- |
| Cash from Financing | 770.50K | 796.00K | 662.20K | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 141.90K | 339.00K | 381.90K | -- | -- |